Select Page

Serum Institute of India will invest $68.24 million in the UK’s Oxford Biomedica, one of the COVID-19 vaccine manufacturers for drug major AstraZeneca. These funds will be used to develop the fallow area at its Oxbox plant into a manufacturing space which is expected to come online in mid-2023.

Read the original article here: